Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom